+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia-Pacific Geriatric Medicine Market 2020-2026

  • PDF Icon


  • October 2020
  • Region: Asia Pacific
  • Orion Market Research Private Limited
  • ID: 5240885
Asia-Pacific Geriatric Medicine Market Size, Share & Trends Analysis Report by Therapeutic (Analgesic, Anticoagulant, Antihypertensive, Antidiabetic, and Others) and by Condition (Cardiovascular Diseases (CVDs), Diabetes, Neurological, Cancer, Respiratory, and Others) and Forecast 2020-2026.

The Asia-Pacific geriatric medicine market is projected to witness a CAGR of 6.8% during the forecast period. The major factors contributing to the growth of the market include the increasing geriatric population and rising prevalence of chronic diseases, such as cardiovascular diseases (CVDs) and cancer. Moreover, the rising industrial sector in these Asia-Pacific economies is further increasing the pollution level and the prevalence of respiratory and other disorders in the geriatric population. These factors combinedly offering growth to the geriatric medicine market in the region.

The geriatric medicine market is classified on the basis of therapeutics and conditions. Based on therapeutics, the market is segmented into analgesic, anticoagulant, antihypertensive, antidiabetic, and others. Based on the condition, the market is segregated into CVDs, diabetes, neurological, cancer, respiratory, and others. Among these conditions, the CVDs segment contributes significantly to the market. The significant contribution of the segment is backed by the significant patient pool of CVDs in the region. With the rise in age, the development of CVDs increases subsequently. Therefore, a huge market is covered by CVDs medicines in the geriatric medicine market.

Geographically, Asia-Pacific geriatric medicine market is analyzed for China, Japan, India, and the Rest of Asia-Pacific. China contributed the major share in Asia-Pacific geriatric medicine market in 2019 and is expected to retain its position during the forecast period. The dominance of China in the Asia-Pacific market is mainly due to the presence of a substantial health workforce in the country. India is projected to exhibit a considerable CAGR in Asia-Pacific geriatric medicine market during the forecast period, owing to the rising geriatric population and expansion of global market players in the country.

The Asia-Pacific geriatric medicine market is influenced by product development and advancements conducted by the market players. Some of the global and key players of the geriatric medicine market include Aurobindo Pharma, Ltd. Mankind Pharma, Cipla Ltd., Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Astellas Pharma Inc., Teva Pharmaceuticals Industries Ltd., and others. These players are playing a significant role in the growth of the geriatric medicine market by providing various products and adopting several strategies such as merger and acquisition, partnerships and collaboration, technological development, and others.

Research Methodology

The market study of the Asia-Pacific geriatric medicine market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for drug manufacturers, pharmaceutical & biopharmaceutical companies, research institutes, academic institutes, industry associates & experts, government organizations, regulatory bodies, and other market participants for overall market analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Asia-Pacific Geriatric Medicine Market Research and Analysis by Therapeutics
2. Asia-Pacific Geriatric Medicine Market Research and Analysis by Condition

The Report Covers:
  • Comprehensive research methodology of the Asia-Pacific geriatric medicine market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Asia-Pacific geriatric medicine market.
  • Insights about market determinants which are stimulating the Asia-Pacific market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Market Determinants
3.1. Motivators
3.2. Restraints
3.3. Opportunities
4. Market Segmentation
4.1. Asia-Pacific Geriatric Medicine Market by Therapeutic
4.1.1. Analgesic
4.1.2. Anticoagulant
4.1.3. Antihypertensive
4.1.4. Antidiabetic
4.1.5. Others (Statins and Antipsychotic)
4.2. Asia-Pacific Geriatric Medicine Market by Condition
4.2.1. Cardiovascular Diseases (CVDs)
4.2.2. Diabetes
4.2.3. Neurological
4.2.4. Cancer
4.2.5. Respiratory
4.2.6. Others (Arthritis and Osteoporosis)
5. Regional Analysis
5.1. China
5.2. Japan
5.3. India
5.4. Rest of Asia-Pacific
6. Company Profiles
6.1. Abbott Laboratories Inc.
6.1.1. Overview
6.1.2. Abbott Laboratories in Asia-Pacific
6.1.3. Abbott Laboratories in Geriatric Medicine Landscape
6.1.4. Recent Developments
6.2. Amgen Inc.
6.3. Astellas Pharma Inc.
6.4. AstraZeneca PLC
6.5. Aurobindo Pharma Ltd.
6.6. Boehringer Ingelheim GmbH
6.7. Bristol-Myers Squibb Co.
6.8. Cipla Ltd.
6.9. Eli Lilly and Co.
6.10. GlaxoSmithKline PLC
6.11. Johnson & Johnson Services Inc.
6.12. Mankind Pharma
6.13. Merck & Co., Inc.
6.14. Novartis AG
6.15. Pfizer Inc.
6.16. Sanofi SA
6.17. Sun Pharmaceutical Industries Ltd.
6.18. Teva Pharmaceutical Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.
  • 6.1.1. Overview
  • 6.1.2. Abbott Laboratories in Asia-Pacific
  • 6.1.3. Abbott Laboratories in Geriatric Medicine Landscape
  • 6.1.4. Recent Developments
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • Cipla Ltd.
  • Eli Lilly and Co.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Mankind Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.